Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Cantor Fitzgerald
Accenture
Colorcon
Medtronic
Dow
Harvard Business School
Baxter
Daiichi Sankyo

Generated: August 16, 2018

DrugPatentWatch Database Preview

Bristol Myers Squibb Company Profile

« Back to Dashboard

Summary for Bristol Myers Squibb
International Patents:447
US Patents:17
Tradenames:66
Ingredients:58
NDAs:77
Patent Litigation for Bristol Myers Squibb: See patent lawsuits for Bristol Myers Squibb

Drugs and US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb STILBETIN diethylstilbestrol TABLET, DELAYED RELEASE;ORAL 004056-014 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb AMNESTROGEN estrogens, esterified TABLET;ORAL 083266-003 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb ZERIT stavudine CAPSULE;ORAL 020412-001 Jun 24, 1994 DISCN No No ➤ Sign Up ➤ Sign Up
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 AB RX Yes No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb SUSTIVA efavirenz CAPSULE;ORAL 020972-001 Sep 17, 1998 6,939,964*PED ➤ Sign Up
Bristol Myers Squibb VIDEX EC didanosine CAPSULE, DELAYED REL PELLETS;ORAL 021183-003 Oct 31, 2000 5,254,539*PED ➤ Sign Up
Bristol Myers Squibb ZERIT stavudine FOR SOLUTION;ORAL 020413-001 Sep 6, 1996 4,978,655*PED ➤ Sign Up
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET, TABLET, TABLET;ORAL 021387-002 Jun 24, 2003 5,030,447*PED ➤ Sign Up
Bristol Myers Squibb SERZONE nefazodone hydrochloride TABLET;ORAL 020152-002 Dec 22, 1994 5,256,664*PED ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16

Non-Orange Book US Patents for Bristol Myers Squibb

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,189,854 Cyclic protein tyrosine kinase inhibitors ➤ Sign Up
8,242,270 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors ➤ Sign Up
7,960,411 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
7,338,963 Lactam-containing compounds and derivatives thereof as factor Xa inhibitors ➤ Sign Up
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB96/049 United Kingdom ➤ Sign Up PRODUCT NAME: STAVUDINE; REGISTERED: UK EU/1/96/009/001 19960508; UK EU/1/96/009/002 19960508; UK EU/1/96/009/003 19960508; UK EU/1/96/009/004 19960508; UK EU/1/96/009/005 19960508; UK EU/1/96/009/006 19960508; UK EU/1/96/009/007 19960508; UK EU/1/96/009/008 19960508; UK EU/1/96/009/009 19960508
13/034 Ireland ➤ Sign Up APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE 2013/034 IN JOURNAL NO. 2325 OF 25/01/2017 UNDER THE HEADING APPLICATION FOR EXTENSION OF THE DURATION OF A SUPPLEMENTARY PROTECTION CERTIFICATE, SPC NO. 2013/034 SHOULD HAVE APPEARED AS FOLLOWS, NOVO NORDISK A/S NOVO ALLE, 2880 BAGSVAERD, DENMARK (20/12/2016) PATENT NO: EP2107069; NOVEL INSULIN DERIVATIVES PRODUCT: INSULIN DEGLUDEC MARKET AUTHORISATION: EU: EU/1/12/807-001, 004, 005, 007-009, 012, 013 AND 015 (21/01/2013) ORIGINAL SPC EXPIRY DATE: 22/01/2028 1127 DESIGNS REGISTERED UNDER THE INDUSTRIAL DESIGNS ACT, 2001
11/024 Ireland ➤ Sign Up PRODUCT NAME: AZTREONAM LYSINE; REGISTRATION NO/DATE: EU/1/09/543/001 20090923
2014000070 Germany ➤ Sign Up PRODUCT NAME: KOMBINATION VON DAPAGLIFLOZIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, UND METFORMIN ODER EINEM PHARMAZEUTISCH VERTRAEGLICHEN SALZ DAVON, GESCHUETZT DURCH DAS GRUNDPATENT EP 1 506 211; REGISTRATION NO/DATE: EU/1/13/900 20140116
3 Finland ➤ Sign Up
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Harvard Business School
US Army
Queensland Health
Cantor Fitzgerald
Merck
Daiichi Sankyo
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.